Stay updated on Texture Analysis Predicts Pembrolizumab Response in Melanoma: Clinical Trial
Sign up to get notified when there's something new on the Texture Analysis Predicts Pembrolizumab Response in Melanoma: Clinical Trial page.

Latest updates to the Texture Analysis Predicts Pembrolizumab Response in Melanoma: Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedLocations for Ontario and Saskatchewan were added and the HHS Vulnerability Disclosure link removed; page revision updated to v3.3.3.SummaryDifference0.3%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check42 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2; this appears to be a backend version update with no impact on study content, eligibility criteria, outcomes, or contacts. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check49 days agoChange DetectedThe funding-status notice warning about potential delays and updates due to funding lapses was removed from the page.SummaryDifference0.4%

- Check63 days agoChange DetectedStudy status updated to Terminated with enrollment closed due to slow accrual; primary outcome analysis was not performed.SummaryDifference0.5%

- Check92 days agoChange DetectedAdded a government-status notice and updated version to v3.2.0; removed the old v3.1.0 tag. The page now communicates current operating status and a new version release.SummaryDifference4%

- Check99 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No changes to core content, pricing, or stock are evident.SummaryDifference0.1%

Stay in the know with updates to Texture Analysis Predicts Pembrolizumab Response in Melanoma: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Texture Analysis Predicts Pembrolizumab Response in Melanoma: Clinical Trial page.